Straumann (OTCMKTS:SAUHY) Shares Gap Up – Still a Buy?

Straumann Holding AG (OTCMKTS:SAUHYGet Free Report)’s share price gapped up prior to trading on Friday . The stock had previously closed at $12.08, but opened at $13.0350. Straumann shares last traded at $13.0350, with a volume of 205 shares.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on SAUHY. UBS Group raised Straumann from a “sell” rating to a “neutral” rating in a report on Tuesday, November 4th. Deutsche Bank Aktiengesellschaft upgraded shares of Straumann from a “hold” rating to a “buy” rating in a research report on Friday, October 31st. Morgan Stanley reiterated an “underweight” rating on shares of Straumann in a research report on Monday, December 15th. The Goldman Sachs Group cut shares of Straumann from a “strong-buy” rating to a “neutral” rating in a research note on Monday, October 13th. Finally, Citigroup restated a “sell” rating on shares of Straumann in a research report on Wednesday, January 14th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Straumann currently has an average rating of “Hold”.

Get Our Latest Stock Analysis on SAUHY

Straumann Price Performance

The firm’s 50 day moving average price is $11.95 and its 200-day moving average price is $11.87.

Straumann Company Profile

(Get Free Report)

Straumann (OTCMKTS:SAUHY) is a Swiss-based dental technology company that develops, manufactures and markets restorative, regenerative and digital solutions for dental professionals. The company’s core offerings center on implant-supported restorations and components, biomaterials used for bone and soft-tissue regeneration, and a range of prosthetic products used by dentists and dental laboratories to restore oral function and aesthetics.

In addition to implant and biomaterial product lines, Straumann provides digital dentistry solutions that support treatment planning and workflows.

Read More

Receive News & Ratings for Straumann Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Straumann and related companies with MarketBeat.com's FREE daily email newsletter.